Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma

Annals of Oncology

Volumn 18, Issue 2, 2007, Pages 249-255

  Choueiri, T K ^a   Rini, B I ^a   Garcia, J A ^a   Baz, R C ^a   Abou Jawde, R M ^a   Thakkar, S G ^a   Elson, P ^a   Mekhail, T M ^a   Zhou, M ^b   Bukowski, R M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Five year survivors; Metastatic renal cell carcinoma; Prognostic factors

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CAPECITABINE; CONSENSUS INTERFERON; FLOXURIDINE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 2; INTERLEUKIN 4;

ADJUVANT THERAPY; ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PANCREAS TUMOR; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCALP TUMOR; SCORING SYSTEM; SOFT TISSUE METASTASIS; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33847284868     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl371     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Javidan J, Stricker HJ, Tamboli P et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999; 162: 1277-1281.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-875.
4. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22: 42-60.
5. DiBiase SJ, Valicenti RK, Schultz D et al. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: Support for dose escalation based on a biological model. J Urol 1997; 158: 746-749.
6. Papac RJ, Keohane MF. Hormonal therapy for metastatic renal cell carcinoma combined androgen and provera followed by high dose tamoxifen. Eur J Cancer 1993; 29A: 997-999.
7. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2. Cancer 1997; 80: 1198-1220.
8. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272-1278.
9. Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol 2003; 44: 65-75.
10. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986; 136: 376-379.
11. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48: 7310-7313.
12. Neves RJ, Zincke H, Taylor WF. Metastatic renal cell cancer and radical nephrectomy: Identification of prognostic factors and patient survival. J Urol 1988; 139: 1173-1176.
13. de Forges A, Rey A, Klink M et al. Prognostic factors of adult metastatic renal carcinoma: A multivariate analysis. Semin Surg Oncol 1988; 4: 149-154.
14. Palmer PA, Vinke J, Philip T et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992; 3: 475-480.
15. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994; 30A: 1310-1314.
16. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995; 154: 35-40.
17. Lopez Hanninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients. J Urol 1996; 155: 19-25.
18. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.
19. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 2000; 34: 246-251.
20. Motzer RJ, Bacik J, Marlani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20: 2376-2381.
21. Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002; 13: 1460-1468.
22. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88: 348-353.
23. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 832-841.
24. Chang DZ, Olencki T, Budd GT et al. Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: Toxicity and pharmacokinetics. Cancer Chemother Pharmacol 2001; 48: 493-498.
25. Olencki T, Peereboom D, Wood L et al. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma. J Cancer Res Clin Oncol 2001; 127: 319-324.
26. Wronski M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology 1996; 47: 187-193.
27. Zhan HC, Gudas LJ, Bok D et al. Differential expression of the enzyme that esterifies retinol, lecithin:rEtinol acyltransferase, in subtypes of human renal cancer and normal kidney. Clin Cancer Res 2003; 9: 4897-4905.
28. Herrem CJ, Tatsumi T, Olson KS et al. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 2005; 11: 226-231.
29. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-811.
30. Shin Lee J, Seok Kim H, Bok Kim Y et al. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol 2003; 84: 166-172.
31. Kim HL, Seligson D, Liu X et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004; 10: 5464-5471.
32. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
33. Motzer R, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 1-8.
34. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
35. Escudier B, Szczylik C, Eisen T et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2005; 23: 16S.